Advanced Breast Cancer Therapies
Advanced Breast Cancer Therapies is a research topic within Pulmonary and Respiratory Medicine. Science Explorer counts 18k research works in it since 1952. 14.4% of them reached the world's top 10% most cited for their field and year.
This cluster of papers focuses on the use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, such as palbociclib, letrozole, ribociclib, and abemaciclib, in the treatment of hormone receptor-positive metastatic breast cancer. The papers cover various aspects including clinical trials, mechanisms of action, therapeutic resistance, combination strategies, and potential biomarkers.
- CDK4/6 Inhibitors
- Breast Cancer
- Palbociclib
- Letrozole
- Ribociclib
- Abemaciclib
- Hormone Receptor-Positive
- Metastatic Breast Cancer
- Cell Cycle Control
- Therapeutic Resistance
- Research works
- 18k fractional, since 1952
- In the world top 10%
- 2.5k per year above
- Top-10% rate
- 14.4% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- +86% the tick is no change
This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.
Which countries lead Advanced Breast Cancer Therapies research?
By volume, the United States and China publish the most (1.6k and 856 works in 2022–2025).
By volume, 2022–2025
- 1 United States 1.6k works
- 2 China 856 works
- 3 Italy 266 works
- 4 Spain 225 works
- 5 India 221 works
- 6 Germany 206 works
- 7 United Kingdom 188 works
- 8 Japan 185 works
- 9 France 179 works
- 10 South Korea 110 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead Advanced Breast Cancer Therapies research?
By volume in 2022–2025, The University of Texas MD Anderson Cancer Center publishes the most Advanced Breast Cancer Therapies research, followed by Dana-Farber Cancer Institute and University of North Carolina at Chapel Hill.
By volume, 2022–2025
- 1 The University of Texas MD Anderson Cancer CenterUnited States 70 works
- 2 Dana-Farber Cancer InstituteUnited States 43 works
- 3 University of North Carolina at Chapel HillUnited States 37 works
- 4 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 36 works
- 5 Memorial Sloan Kettering Cancer CenterUnited States 36 works
- 6 Harvard UniversityUnited States 26 works
- 7 Massachusetts General HospitalUnited States 25 works
- 8 Fudan University Shanghai Cancer CenterChina 22 works
- 9 Istituti di Ricovero e Cura a Carattere ScientificoItaly 21 works
- 10 Pfizer (United States)United States 20 works
Who are the leading researchers in Advanced Breast Cancer Therapies?
The most-cited researchers publishing on Advanced Breast Cancer Therapies include Charles M. Perou, Gordon B. Mills and Larry Rubinstein.
- 1 Charles M. Perou United States 4.2k citations
- 2 Gordon B. Mills United States 3.7k citations
- 3 Larry Rubinstein United States 3.6k citations
- 4 Jan Bogaerts Belgium 3.4k citations
- 5 Adi F. Gazdar United States 3.3k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is Advanced Breast Cancer Therapies research done?
The largest centres of Advanced Breast Cancer Therapies research in 2022–2025 are New York (United States), Beijing (China), Boston (United States) and Houston (United States).
Largest cities, 2022–2025
Where is the best place to study Advanced Breast Cancer Therapies?
Among universities, judged by research, China Pharmaceutical University, University of Milan and Chinese Academy of Medical Sciences & Peking Union Medical College score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.
| # | University | Score | Top 10% | Specialisation | Works | Growth |
|---|---|---|---|---|---|---|
| 1 | China Pharmaceutical UniversityChina | 55.9 | 35.7% | 8.1× | 9 | +128.5% |
| 2 | University of MilanItaly | 55.3 | 43.6% | 3.6× | 12 | +148.0% |
| 3 | Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina | 54.0 | 15.0% | 7.4× | 36 | +135.0% |
| 4 | Harvard UniversityUnited States | 50.0 | 26.4% | 4.1× | 26 | +99.1% |
| 5 | Sichuan UniversityChina | 41.5 | 27.3% | 1.6× | 14 | +203.6% |
| 6 | Sun Yat-sen UniversityChina | 40.5 | 18.1% | 2.3× | 19 | +436.9% |
| 7 | University of North Carolina at Chapel HillUnited States | 40.3 | 8.5% | 4.4× | 38 | +126.4% |
| 8 | Icahn School of Medicine at Mount SinaiUnited States | 40.1 | 9.0% | 5.4× | 13 | +215.5% |
| 9 | China Medical UniversityChina | 39.9 | 13.7% | 5.8× | 10 | +299.2% |
| 10 | University of California, San FranciscoUnited States | 38.6 | 18.0% | 5.2× | 17 | +55.2% |
Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.
Is Advanced Breast Cancer Therapies research growing?
Output in 2018–2022 was 86% higher than in 2013–2017, peaking in 2026. The fastest-growing topics are Advanced Breast Cancer Therapies.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.